Fuzeon (enfuvirtide) is the first drug in a class of anti-HIV drugs known as fusion inhibitors. These drugs prevent HIV from infecting CD4 (white blood) cells.

HIV-druginteractions.org provides up-to-date, comprehensive, and reliable information about interactions between anti-HIV drugs and other drugs. It also features HIV-related articles which are updated on a regular basis.

Intelence (etravirine) belongs to a class of anti-HIV drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTIs), which bind to and block the action of reverse transcriptase, an essential protein that HIV needs in order to replicate.

Invirase (saquinavir mesylate) is a protease inhibitor. It blocks the action of the protease enzyme, preventing HIV from making copies of itself.

Isentress (raltegravir) is an antiretroviral medication that blocks the action of the enzyme integrase. This disables HIV from making copies of itself. When used in combination with other anti-HIV medications, Isentress can lower HIV viral loads and help increase CD4 cell counts.

Kaletra (lopinavir/ritonavir) belongs to a class of anti-HIV drugs known as protease inhibitors, which are known to reduce the amount of HIV in the blood and to increase the number of CD4 cells in the body. Kaletra is a combination of two drugs and can be prescribed in either a once daily or twice daily dosage.

Lexiva (fosamprenavir) belongs to a class of anti-HIV drugs known as protease inhibitors, which are known to reduce the amount of HIV in the blood and to increase the number of CD4 cells in the body.

Norvir (ritonavir) belongs to a class of anti-HIV drugs known as protease inhibitors, which are known to reduce the amount of HIV in the blood and to increase the number of CD4 cells in the body.

Prezista (darunavir) belongs to a class of anti-HIV drugs known as protease inhibitors, which are known to reduce the amount of HIV in the blood and to increase the number of CD4 cells in the body.

Rescriptor (delavirdine) belongs to a class of anti-HIV drugs known as non-nucleoside reverse transcriptase inhibitors, which bind to and block the action of reverse transcriptase, an essential protein that HIV needs in order to replicate. Rescriptor is not approved for use in HIV-positive children and is not recommended as an NNRTI option for adults beginning HIV therapy for the first time.